These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33836624)

  • 1. Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based regimens: a
    Wang J; Park C; Arroyo-Suarez R
    Leuk Lymphoma; 2021 Sep; 62(9):2219-2226. PubMed ID: 33836624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis.
    Wang J; Kim Y
    Int J Hematol; 2020 Nov; 112(5):650-657. PubMed ID: 32710431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs.
    Dima D; Li A; Granat LM; Dhillon P; Chamseddine F; Yalamanchali A; Mirzai S; Wei W; Samaras CJ; Valent J; Anwer F; Khouri J
    Br J Haematol; 2023 Apr; 201(2):280-284. PubMed ID: 36604838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
    Chakraborty R; Bin Riaz I; Malik SU; Marneni N; Mejia Garcia A; Anwer F; Khorana AA; Rajkumar SV; Kumar S; Murad MH; Wang Z; Khan SU; Majhail NS
    Cancer; 2020 Apr; 126(8):1640-1650. PubMed ID: 31913498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents.
    Calafiore V; Giamporcaro S; Conticello C; Romano A; Parisi M; Giuffrida G; Tibullo D; Di Raimondo F; Signorelli SS
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32899553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study.
    Covut F; Ahmed R; Chawla S; Ricaurte F; Samaras CJ; Anwer F; Garcia AVM; Angelini DE; Mazzoni S; Faiman B; Valent J; Khouri J
    Br J Haematol; 2021 Jun; 193(6):1213-1219. PubMed ID: 33997961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.
    Sanfilippo KM; Luo S; Wang TF; Fiala M; Schoen M; Wildes TM; Mikhael J; Kuderer NM; Calverley DC; Keller J; Thomas T; Carson KR; Gage BF
    Am J Hematol; 2019 Nov; 94(11):1176-1184. PubMed ID: 31379000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy.
    Covut F; Sanfilippo KM
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):363-367. PubMed ID: 36485142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma.
    Bravo-Perez C; Fernández-Caballero M; Soler-Espejo E; Garcia-Torralba E; Sorigue M; García-Malo MD; Jerez A; Vicente V; Roldán V; de Arriba F
    J Thromb Thrombolysis; 2021 Oct; 52(3):848-853. PubMed ID: 33649980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
    Chari A; Rodriguez-Otero P; McCarthy H; Suzuki K; Hungria V; Sureda Balari A; Perrot A; Hulin C; Magen H; Iida S; Maisnar V; Karlin L; Pour L; Parasrampuria DA; Masterson T; Kosh M; Yang S; Delioukina M; Qi M; Carson R; Touzeau C
    Br J Haematol; 2021 Mar; 192(5):869-878. PubMed ID: 33216361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).
    San-Miguel J; Usmani SZ; Mateos MV; van de Donk NWCJ; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Liu K; Hellemans P; Masterson T; Clemens PL; Luo M; Farnsworth A; Nahi H; Chari A
    Haematologica; 2021 Jun; 106(6):1725-1732. PubMed ID: 32354874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma.
    Li A; Wu Q; Luo S; Warnick GS; Zakai NA; Libby EN; Gage BF; Garcia DA; Lyman GH; Sanfilippo KM
    J Natl Compr Canc Netw; 2019 Jul; 17(7):840-847. PubMed ID: 31319391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the risk of venous thromboembolism in multiple myeloma.
    Sanfilippo KM
    Thromb Res; 2020 Jul; 191 Suppl 1():S74-S78. PubMed ID: 32736783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thromboprophylaxis in multiple myeloma.
    Thalambedu N; Al Hadidi S
    Leuk Lymphoma; 2022 Dec; 63(12):2807-2815. PubMed ID: 35759648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort.
    Chalayer E; Talbot A; Frenzel L; Karlin L; Collet P; Guyotat D; Attal M; Leleu X; Tardy B
    J Thromb Haemost; 2022 Aug; 20(8):1859-1867. PubMed ID: 35557490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.
    Mateos MV; Rigaudeau S; Basu S; Spicka I; Schots R; Wrobel T; Cook G; Beksac M; Gries KS; Kudva A; Tromp B; Van Rampelbergh R; Pei H; Wroblewski S; Carson R; Delioukina M; White D
    J Oncol Pharm Pract; 2023 Jul; 29(5):1172-1177. PubMed ID: 36067063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
    Zangari M; Fink L; Zhan F; Tricot G
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venous thromboembolism in patients with myeloma: incidence and risk factors in a "real-world" population.
    Crowley MP; Eustace JA; O'Shea SI; Gilligan OM
    Clin Appl Thromb Hemost; 2014 Sep; 20(6):600-6. PubMed ID: 24486624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
    Bradbury CA; Craig Z; Cook G; Pawlyn C; Cairns DA; Hockaday A; Paterson A; Jenner MW; Jones JR; Drayson MT; Owen RG; Kaiser MF; Gregory WM; Davies FE; Child JA; Morgan GJ; Jackson GH
    Blood; 2020 Aug; 136(9):1091-1104. PubMed ID: 32438407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.